Glutamatergic & synaptic plasticity
One of 6 mechanistic pathways to 🧠 Focus, memory & cognition · 13 options
Long-term potentiation — the cellular basis of learning — runs through AMPA and NMDA receptors. Modulating them raises the ceiling on how readily new connections form, and it is also the pathway where excitotoxicity is a real rather than theoretical concern.
Magnesium is a physiological NMDA-receptor blocker, so low magnesium leaves glutamate signaling unopposed — which feels like anxiety and poor recall rather than a deficiency.
Magnesium, RBCVitamin D (25-Hydroxy)hs-CRP (High-Sensitivity C-Reactive Protein)Homocysteine🧠 Brain Fog & Cognition covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Sunifiram
An ampakine reported to be far more potent than piracetam in rodent models, acting on AMPA and glycine sites. Essentially no human safety data — the enthusiasm outruns the evidence badly.
💉 TAK-653
An AMPA-receptor positive allosteric modulator: it does not open the channel, it makes the receptor answer the glutamate already there. That distinction is the safety argument — the earlier AMPA potentiators carried a seizure liability precisely because they drove the receptor directly, and this one was engineered for a wide margin between the pro-cognitive and the pro-convulsant dose. Phase-1 human work is as far as it has gone.
💉 Neboglamine
A positive modulator at the NMDA glycine site, developed for schizophrenia. The cognitive-enhancement use is entirely extrapolated from that program.
💉 Fasoracetam
Upregulates metabotropic glutamate receptors and acts on GABA-B. Trialed in adolescent ADHD with mGluR mutations, which is an unusually specific and mechanistically satisfying use case.
💉 Dihexa
An angiotensin-IV analog acting on the HGF/c-Met pathway, reported to be seven orders of magnitude more potent than BDNF at promoting synaptogenesis in vitro. That number is extraordinary and it is entirely preclinical — no human safety data of any kind exists.
💉 PRL-8-53
A single 1970s human trial showed dramatic improvement in word recall, particularly in poor baseline performers. Never replicated in fifty years, which is itself informative.
💉 P-21
A Cerebrolysin-derived peptide fragment reported to increase neurogenesis and BDNF in animals.
💉 NSI-189
Increases hippocampal neurogenesis and volume in animal models. A human depression trial missed its primary endpoint while showing cognitive improvement on secondary measures — an interesting failure.
💉 9-ME-BC
A beta-carboline that raises dopamine and shows neurotrophic and neuroprotective effects in cell models. Some beta-carbolines have genotoxicity concerns, which deserves more scrutiny than it gets.
🧬 Magnesium L-Threonate
The magnesium form shown to raise brain magnesium specifically, increasing synaptic density in animals and improving cognitive measures in a human trial.
🧬 Lion's Mane
Hericenones and erinacines stimulate NGF synthesis. A Japanese trial showed improved cognitive scores in older adults that reverted after stopping — meaning the effect requires ongoing use.
💉 Memantine
The only widely used dementia drug on the glutamate side rather than the acetylcholine side: a low-affinity uncompetitive open-channel NMDA antagonist, which blocks the background leak of an over-activated receptor while stepping aside for the bursts that carry signal. Approved for moderate to severe Alzheimer's dementia only. In the largest pooled dataset it did not clear the reviewers' own threshold for clinical importance as a single agent. Renal clearance falls about 80% at urine pH 8, which is what bicarbonate loading does. No buy button.
💉 Aviandr
AVN-101, sold as a 5-HT6 antagonist. Its own developers' binding data says otherwise: 5-HT7 at Ki 153 pM, histamine H1 at 0.58 nM and three adrenergic alpha-2 subtypes all bind tighter than 5-HT6 does at 1.2-2.0 nM, so there is no dose at which it is selective and the H1 number predicts sedation rather than sharpening. The 5-HT6 thesis itself failed in 1,315 patients at phase 3 and 564 at phase 2. Its entire human record is one phase I.
What actually decides this outcome, in order of size
Long-term potentiation is the cellular correlate of learning and it runs on calcium entering through NMDA receptors when AMPA depolarization removes the magnesium block. The same calcium, in excess, is how neurons die. Ranked by how much of the outcome each factor owns:
- Whether anything is being learned, which the pharmacology cannot supply. Plasticity is a capacity, not a content. Raising the probability that a synapse strengthens does nothing if no synapse is being driven. This is the largest determinant here and it is training, not a molecule.
- THE DOSE CEILING, which for this receptor family is set by the seizure end and not by the efficacy end. The translational history of the AMPA receptor as a drug target has been reviewed directly Miyazaki 2021, and the ligand chemotypes and binding modes are catalogued Golubeva 2022. This is why the modern programs are described as low-impact positive modulators rather than agonists: the class was constrained by the top of the curve from the beginning.
- How far the class has actually traveled in humans, which is further than this page's items and still not far. TAK-653 has central nervous system effects reported in humans Dijkstra 2022, with transcranial magnetic stimulation used as a translational biomarker for AMPA receptor modulation O'Donnell 2021. The NMDA side has its own review of therapeutic potential in psychiatry Hanson 2023. Those are the reference points; most items below have nothing comparable.
- Which receptor and which site, because the page treats them as one and they are not. Sunifiram acts at a glycine-binding site to enhance hippocampal synaptic efficacy Moriguchi 2013, with AMPA receptor activation implicated in its antiamnesic effect Galeotti 2003. Nefiracetam potentiates NMDA receptor function through protein kinase C Moriguchi 2007. Neboglamine was characterized as facilitating glycine effects Lanza 1997. Fasoracetam is a metabotropic glutamate story Ogasawara 1999 with a clinical report in adolescents carrying metabotropic glutamate receptor network mutations Elia 2018.
- Whether the compound is a plasticity drug at all. Dihexa belongs to a neurotrophic peptide series built on an adamantane scaffold Li 2010; P-21 descends from a ciliary neurotrophic factor peptide with hippocampal neurogenesis data Blanchard 2010; NSI-189 is a neurogenesis compound with plasticity and functional reversal data in a mouse model Liu 2019; 9-ME-BC is a dopaminergic and neurotrophic beta-carboline Gruss 2012. Four different mechanisms filed under one heading.
- Magnesium status, which is the only item here that is physiology rather than pharmacology. Magnesium occupies the NMDA channel at rest, so it is a component of the system rather than a modulator of it, and Magnesium L-Threonate is the formulation argument built on that.
The order to run these in, and what has to be true first
This is the pathway on the site with the widest gap between mechanistic interest and human data, so the order below is by how much is known rather than by how promising anything sounds.
- Establish that the complaint is plasticity rather than something correctable. TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine), Vitamin B12 with Homocysteine, and Ferritin. None of these is glamorous and each has a treatment.
- Magnesium L-Threonate first, because it is the only physiological entry point here. Correcting a magnesium deficit is a different act from modulating a receptor, and Magnesium, RBC is the measurement that says which one you are doing.
- Lion's Mane is the botanical neurotrophic argument and sits here for the same reason: low risk, modest expectation. It belongs to the growth-factor half of this page rather than the receptor half.
- TAK-653 is the item with real human pharmacodynamic work. Central effects have been characterized in humans Dijkstra 2022 using an objective cortical biomarker O'Donnell 2021. It is an investigational compound and that is the correct frame for it.
- Sunifiram and Neboglamine are preclinical site-specific modulators. The sunifiram work is hippocampal electrophysiology Moriguchi 2013 Galeotti 2003; the neboglamine work is receptor characterization Lanza 1997. Neither has a human efficacy program.
- Fasoracetam has the most specific human claim on the page and the narrowest one. The clinical report is in adolescents selected for metabotropic glutamate receptor network mutations Elia 2018, which is a pharmacogenetic result rather than a general nootropic one.
- Dihexa, P-21 and NSI-189 are neurotrophic rather than glutamatergic Li 2010 Blanchard 2010 Liu 2019, and 9-ME-BC is a beta-carboline with dopaminergic and neurotrophic actions Gruss 2012. Detail on the growth-factor side is at BDNF & neurotrophic signaling.
- PRL-8-53 is a single small human study from the 1970s and should be described that way rather than ranked. Nothing has replicated it in fifty years, and the absence of a replication is itself information.
What gets bought for this that cannot move it
The category that fails structurally is the direct AMPA agonist sold as a stronger version of a modulator. The reason the pharmaceutical programs on this receptor are positive allosteric modulators rather than agonists is that the therapeutic window is bounded above by convulsant activity — the translational history of the target says so plainly Miyazaki 2021, and the ligand chemotypes were developed within that constraint Golubeva 2022. A research chemical bought from a website with no dose-response characterization in humans is being taken on the assumption that the dangerous end is far away, and the whole medicinal-chemistry effort in this class exists because it is not.
The direction problem is that potentiation and excitotoxicity are not two effects. They are the same calcium current at different magnitudes. That is why NMDA-directed psychiatry has moved toward modulation rather than activation Hanson 2023, and it is why 'stronger' has never been the goal in the published programs. On this page, more is the failure mode rather than the upgrade.
Two honest limits on the item list. The compound with the most specific human claim, Fasoracetam, earned it in a selected genotype Elia 2018 rather than in the general population. And several items here are not glutamatergic at all Li 2010 Blanchard 2010 Liu 2019 Gruss 2012 — filing them together implies a shared mechanism the pharmacology does not support, and it is the reason people stack two things that are doing the same job and none that is doing the other.
If the goal underneath is different, so is the page. If acetylcholine and encoding are the actual target, Cholinergic — attention, encoding & recall. If it is growth factor signaling, BDNF & neurotrophic signaling. If it is inflammation or membrane integrity, Neuroinflammation & membrane integrity. And anybody with a seizure history, a head injury history, or on a medication that lowers seizure threshold should treat this entire pathway as a conversation with a doctor rather than a purchase.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Nothing here will move a blood marker in a healthy adult, so the read-out is a task score and the bloods are safety; and any effect worth having on a plasticity pathway shows up as a faster learning curve on repeated practice rather than as a feeling on the day.
- A repeated learning task, same task, same time of day, baseline and weekly for eight weeks. Plasticity is a rate of change, so the shape of the curve across sessions is the measurement and a single score is not. Eight weeks because that is the shortest window in which a slope is distinguishable from a good day.
- Magnesium, RBC at baseline and 12 weeks on Magnesium L-Threonate. Red cell magnesium rather than serum, because serum is tightly regulated and moves last; twelve weeks because red cell turnover sets the integration window.
- Comprehensive Metabolic Panel (CMP) at baseline and 12 weeks on any research chemical here. These are compounds without healthy-adult safety programs, and transaminases and renal function are the cheapest early warning available.
- Vitamin B12 with Homocysteine and TSH (Thyroid-Stimulating Hormone) once at the start. The correctable causes of a plasticity complaint, checked before spending anything.
- hs-CRP (High-Sensitivity C-Reactive Protein) at baseline and 12 weeks, as falsification. If a compound here is doing something systemic, this is where it would show, and the honest expectation is a flat line.
What will fool you. Practice effects are large on exactly the tasks people use to test themselves, which is why the baseline has to be repeated before the compound starts rather than measured once. Anything sedating or stimulating taken alongside will swamp the signal. An objective cortical biomarker of AMPA modulation exists in research settings O'Donnell 2021 and is not something a reader can order, so there is no way to verify target engagement at home. Preclinical electrophysiology Moriguchi 2013 Moriguchi 2007 Lanza 1997 is not a human dose. And a compound that makes learning feel effortless is more likely to be acting on drive than on plasticity, which is a different page.
Sources read for these sections
- Miyazaki T. Translational medicine of the glutamate AMPA receptor. Proc Jpn Acad Ser B Phys Biol Sci 2021 · PMID 33431723
- Hanson JE. Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology 2023 · PMID 37369776
- Dijkstra F, et al. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Translational Psychiatry 2022 · PMID 36153330
- O'Donnell P, et al. Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation. Translational Psychiatry 2021 · PMID 34045439
- Golubeva EA, et al. Diversity of AMPA Receptor Ligands: Chemotypes, Binding Modes, Mechanisms of Action, and Therapeutic Effects. Biomolecules 2022 · PMID 36671441
- Moriguchi S, Tanaka T, Narahashi T. Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor.. Hippocampus 2013 · PMID 23733502
- Galeotti N, Ghelardini C, Pittaluga A. AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram).. Naunyn Schmiedebergs Arch Pharmacol 2003 · PMID 14600801
- Moriguchi S, Shioda N, Maejima H. Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.. Mol Pharmacol 2007 · PMID 17095583
- Lanza M, Bonnafous C, Colombo S. Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex.. Neuropharmacology 1997 · PMID 9294970
- Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.. Nat Commun 2018 · PMID 29339723
- Ogasawara T. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer.. Pharmacol Biochem Behav 1999 · PMID 10494996
- Liu Y, et al. Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189. Neuropharmacology 2019 · PMID 30408487
- Li B, Wanka L, et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters 2010 · PMID 20600002
- Gruss M, Appenroth D, Flubacher A, Enzensperger C, Bock J, Fleck C, Gille G, Braun K. 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation. Journal of Neurochemistry 2012;121(6):924-931 · PMID 22380576
- Blanchard J, et al. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. Journal of Alzheimers Disease 2010 · PMID 20952820
The other 5 routes to focus, memory & cognition
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Focus, memory & cognition Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Focus, memory & cognition Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
Long-term potentiation — the cellular basis of learning — runs through AMPA and NMDA receptors. Modulating them raises the ceiling on how readily new connections form, and it is also the pathway where excitotoxicity is a real rather than theoretical concern.
13 options are mapped to this pathway in the Vault, including Sunifiram, TAK-653, Neboglamine, Fasoracetam. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 3 carry clinical validation and 10 are mechanistic predictions.
Magnesium is a physiological NMDA-receptor blocker, so low magnesium leaves glutamate signaling unopposed — which feels like anxiety and poor recall rather than a deficiency. The markers worth checking are Magnesium, RBC, Vitamin D (25-Hydroxy), hs-CRP (High-Sensitivity C-Reactive Protein), Homocysteine.
Unproven is not the same as ineffective. Of the 13 options on this pathway, 3 have clinical validation and 10 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Glutamatergic & synaptic plasticity. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.